標題: Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells
作者: Chen, Ruey-Shyang
Ko, Jen-Chung
Chiu, Hsien-Chun
Wo, Ting-Yu
Huang, Yi-Jhen
Tseng, Sheng-Chieh
Chen, Huang-Jen
Huang, Yu-Ching
Jian, Yi-Jun
Lee, Wei-Ting
Lin, Yun-Wei
科技法律研究所
Institute of Technology Law
關鍵字: ERCC1;p38MAPK;Resveratrol;Pemetrexed;Nonsmall cell lung cancer
公開日期: 1-Dec-2013
摘要: The multitargeted antifolate pemetrexed has demonstrated certain clinical activities against nonsmall cell lung cancer (NSCLC). Resveratrol (3,5,4-trihydroxy-trans-stilbene) is a polyphenol found in grapes and other plants and has great potential as a preventative and therapeutic agent due to its anticarcinogenic activity. The efficacy of adding resveratrol to pemetrexed to prolong the survival of patients with NSCLC still remains unclear. The excision repair cross-complementation 1 (ERCC1) is a DNA repair gene coding 5' endonuclease in nucleotide excision repair and is overexpressed in chemo- or radioresistant carcinomas. In this study, resveratrol (10-50 mu M) inhibited cell survival in two NSCLC cells, H520 and H1975. Treatment with resveratrol increased ERCC1 messenger RNA and protein levels in a MKK3/6-p38 MAPK signal activation-dependent manner. Furthermore, blocking p38 MAPK activation by SB202190 or knocking down ERCC1 expression by transfection with small interfering RNA of ERCC1 enhanced the cytotoxicity of resveratrol. Combining resveratrol with pemetrexed resulted in a synergistic cytotoxic effect, accompanied with the reduction of phospho-p38 MAPK and ERCC1 protein levels, and a DNA repair capacity. Expression of constitutively active MKK6 (MKK6E) or HA-p38 MAPK vectors significantly rescued the decreased p38 MAPK activity, and restored ERCC1 protein levels and cell survival in resveratrol and pemetrexed cotreated NSCLC cells. In this study, for the first time, we have demonstrated the synergistic effect of combined treatment with resveratrol and pemetrexed in human NSCLC cells through downregulation of the MKK3/6-p38 MAPK-ERCC1 signal, suggesting a potential benefit of combining resveratrol and pemetrexed to treat lung cancer in the future.
URI: http://dx.doi.org/10.1007/s00210-013-0905-9
http://hdl.handle.net/11536/23243
ISSN: 0028-1298
DOI: 10.1007/s00210-013-0905-9
期刊: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
Volume: 386
Issue: 12
起始頁: 1047
結束頁: 1059
Appears in Collections:Articles


Files in This Item:

  1. 000327092100005.pdf